Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simak Ali

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Cell Death & Disease|March 17, 2017
Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutationsJoel Fulton, Bismoy Mazumder, Jonathan B Whitchurch, et al.
British Journal of Cancer|February 14, 2024
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Nature Genetics|January 24, 2017
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancerLuca Magnani, Gianmaria Frige, Raffaella Maria Gadaleta, et al.
Nucleic Acids Research|September 20, 2013
Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cellsChun-Fui Lai, Koen D Flach, Xanthippi Alexi, et al.
Nature Communications|November 28, 2015
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Nature Communications|August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Breast Cancer Research and Treatment|July 8, 2010
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cellsPaul T R Thiruchelvam, Chun-Fui Lai, Hui Hua, et al.
Breast Cancer Research and Treatment|August 24, 2010
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growthRobert S Tolhurst, Ross S Thomas, Fiona J Kyle, et al.
Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Cell Death & Disease|March 17, 2017
Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutationsJoel Fulton, Bismoy Mazumder, Jonathan B Whitchurch, et al.
British Journal of Cancer|February 14, 2024
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Nature Genetics|January 24, 2017
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancerLuca Magnani, Gianmaria Frige, Raffaella Maria Gadaleta, et al.
Nucleic Acids Research|September 20, 2013
Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cellsChun-Fui Lai, Koen D Flach, Xanthippi Alexi, et al.
Nature Communications|November 28, 2015
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Nature Communications|August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Breast Cancer Research and Treatment|July 8, 2010
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cellsPaul T R Thiruchelvam, Chun-Fui Lai, Hui Hua, et al.
Breast Cancer Research and Treatment|August 24, 2010
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growthRobert S Tolhurst, Ross S Thomas, Fiona J Kyle, et al.
Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Pageof 12